With twice-weekly dosing, alternating between left and right sides of the abdomen is usually sufficient
The current surge in demand began in 2017, when Novo Nordisk released Ozempic to the market
What Will Happen When the Bridge Program Ends in 18 Months
Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide
Binding to the GLP-1 receptor promotes insulin secretion in a glucose-dependent manner, slows gastric emptying, and reduces appetite through central nervous system signaling, aiding in glycemic control and weight loss
GLP-1RAs, such as lixisenatide, not only rely on -cell function and glucagon suppression, but also assist to lower glucose by other (insulin-independent) mechanisms such as delayed gastric emptying, underlying the clinical utility of GLP-1RAs as adjuvant therapy to basal insulin in longstanding T2DM [14]